Biotech Veteran Richard van den Broek Joins Corvus Board to Support ITK Inhibition Strategy

Corvus Pharmaceuticals has announced the appointment of seasoned biotech investor and analyst Richard van den Broek to its board of directors. With over three decades of experience in the life sciences sector—including leadership roles as a board member, equity research analyst, and investor—van den Broek brings deep strategic insight to Corvus as it advances its ITK inhibitor programs. His addition signals a strengthening of the company’s board as it sharpens its focus on modulating immune signaling pathways to tackle cancer and immune diseases.

Van den Broek, managing partner at HSMR Advisors, has previously held board roles at several high-impact biotech firms, including Pharmacyclics, where he played a role in ushering the first BTK inhibitor to market. Drawing on that success, he expressed optimism about Corvus' potential to break new ground in ITK inhibition. His financial acumen and biotech foresight are expected to provide invaluable guidance as Corvus continues to push innovative therapies through clinical development.